KCNA5抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse spleen tissue, Primary antibody: P07403(KCNA5 Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 60 seconds    

  
  

The KCNA5 antibody targets the Kv1.5 protein, encoded by the KCNA5 gene, which belongs to the voltage-gated potassium channel family. Kv1.5 is primarily expressed in cardiac atrial myocytes, where it mediates the ultra-rapid delayed rectifier potassium current (IKur), a key regulator of atrial action potential repolarization. This channel plays a critical role in maintaining normal heart rhythm, and mutations or dysregulation of KCNA5 are linked to atrial fibrillation (AF) and other cardiac arrhythmias. KCNA5 antibodies are widely used in research to study channel expression, localization, and function in both physiological and pathological contexts.

In autoimmune contexts, anti-KCNA5 autoantibodies have been detected in patients with certain connective tissue diseases, such as systemic sclerosis or lupus, and are associated with acquired atrial arrhythmias. These autoantibodies may disrupt channel activity, contributing to electrical remodeling and AF pathogenesis.

As a research tool, KCNA5 antibodies are applied in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate channel distribution in tissues or assess protein levels in disease models. They also aid in drug discovery, particularly in screening compounds targeting IKur for antiarrhythmic therapies. However, commercial KCNA5 antibodies vary in specificity, requiring careful validation to ensure accurate detection. Overall, KCNA5 antibodies serve as essential probes for unraveling the channel's role in cardiac electrophysiology and its implications in arrhythmogenic disorders.